In turn, the jury has put Amgen on the hook to pay Regeneron $135.6 million in compensatory damages and another $271.2 million in punitive damages, according to a verdict form filed Thursday.

Amgen is committed to supporting patients with IgG4-RD and helping appropriate patients with access to UPLIZNA. Patients and caregivers who need support, tools or resources can contact Amgen By ...

Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously ...

To interact with La La in her new video, access resources to help facilitate an open conversation about plaque psoriasis treatment with your doctor and learn about Otezla ... filed by Amgen, including ...

La La is not currently on treatment or taking Otezla. Amgen is committed ... Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic ...

Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Amgen also purchased oral immunology drug Otezla, which fits well with the ... have generated promising data and could begin to support growth within the next few years. Amgen's pipeline had ...